IN2012DN03361A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03361A
IN2012DN03361A IN3361DEN2012A IN2012DN03361A IN 2012DN03361 A IN2012DN03361 A IN 2012DN03361A IN 3361DEN2012 A IN3361DEN2012 A IN 3361DEN2012A IN 2012DN03361 A IN2012DN03361 A IN 2012DN03361A
Authority
IN
India
Prior art keywords
microparticles
disclosed
treating
macular
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Heather Nettles
Angela Stella
Original Assignee
Evonik Degussa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Degussa Corp filed Critical Evonik Degussa Corp
Publication of IN2012DN03361A publication Critical patent/IN2012DN03361A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN3361DEN2012 2009-10-01 2010-10-01 IN2012DN03361A (enrdf_load_stackoverflow)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24784909P 2009-10-01 2009-10-01
US24784809P 2009-10-01 2009-10-01
PCT/US2010/051068 WO2011041642A1 (en) 2009-10-01 2010-10-01 Microparticle compositions and methods for treating age-related macular degeneration

Publications (1)

Publication Number Publication Date
IN2012DN03361A true IN2012DN03361A (enrdf_load_stackoverflow) 2015-10-23

Family

ID=43085447

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3361DEN2012 IN2012DN03361A (enrdf_load_stackoverflow) 2009-10-01 2010-10-01

Country Status (7)

Country Link
US (1) US20110104151A1 (enrdf_load_stackoverflow)
EP (1) EP2482804A1 (enrdf_load_stackoverflow)
JP (1) JP2013506693A (enrdf_load_stackoverflow)
KR (1) KR20120095371A (enrdf_load_stackoverflow)
CA (1) CA2776472A1 (enrdf_load_stackoverflow)
IN (1) IN2012DN03361A (enrdf_load_stackoverflow)
WO (1) WO2011041642A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166287A1 (en) * 2011-05-27 2012-12-06 Novartis Ag Method of treating vision disorders
CN103957898B (zh) * 2011-11-18 2016-02-24 瑞泽恩制药公司 聚合物蛋白微粒
KR102183727B1 (ko) * 2012-01-23 2020-11-27 알러간, 인코포레이티드 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
KR20150058510A (ko) * 2012-09-27 2015-05-28 알레간 인코포레이티드 단백질의 지속된 방출을 위한 생물분해성 약물 전달 시스템
KR20150128857A (ko) 2013-03-14 2015-11-18 알러간, 인코포레이티드 지속된-방출 전달의 조성물 및 제조 공정 동안 단백질을 안정화시키는 방법
KR102016421B1 (ko) 2016-10-28 2019-08-30 부산대학교 산학협력단 치자 추출물로 표면 처리된 금 나노입자를 유효성분으로 함유하는 황반변성 예방 또는 치료용 조성물
KR20200029374A (ko) * 2018-09-10 2020-03-18 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
GB201906835D0 (en) * 2019-05-15 2019-06-26 Ucb Biopharma Sprl Dry microparticles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE69024953T3 (de) 1989-05-04 2005-01-27 Southern Research Institute, Birmingham Einkapselungsverfahren
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
EP2311433A3 (en) * 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
US20060246146A1 (en) * 2005-04-29 2006-11-02 Mcmahon Robert J Method of increasing the salivary sialic acid content in a mammal
US7918814B2 (en) * 2006-05-02 2011-04-05 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2008002657A2 (en) * 2006-06-28 2008-01-03 Surmodics, Inc. Microparticles containing active agent dispersed in a polymer matrix as implant or as coating for medical devices
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
JP2012515790A (ja) * 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ， インコーポレイテッド 微粒子製造のための連続二重エマルジョン工程

Also Published As

Publication number Publication date
US20110104151A1 (en) 2011-05-05
KR20120095371A (ko) 2012-08-28
WO2011041642A1 (en) 2011-04-07
CA2776472A1 (en) 2011-04-07
JP2013506693A (ja) 2013-02-28
EP2482804A1 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
PH12020550450A1 (en) Certain chemical entities, compositions and methods
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
IN2012DN03361A (enrdf_load_stackoverflow)
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
IN2012DN02469A (enrdf_load_stackoverflow)
GB201118656D0 (en) New compounds
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
GB201209613D0 (en) New compounds
PH12013502240B1 (en) Novel compounds as modulators of protein kinase
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
SG10201903119QA (en) Polypeptide vaccine
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2015007916A (es) Peri-carbinoles.
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
MX2012006430A (es) Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
TN2014000131A1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
MX336711B (es) Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos.
IN2015KN00492A (enrdf_load_stackoverflow)
WO2011127048A3 (en) NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.